-
Views
-
Cite
Cite
L. Wideroff, M. H. Schiffman, B. Nonnenmacher, N. Hubbert, R. Kirnbauer, C. E. Greer, D. Lowy, A. T. Lorincz, M. M. Manos, A. G. Glass, D. R. Scott, M. E. Sherman, R. J. Kurman, J. Buckland, R. E. Tarone, J. Schiller, Evaluation of Seroreactivity to Human Papillomavirus Type 16 Virus-like Particles in an Incident Case-Control Study of Cervical Neoplasia, The Journal of Infectious Diseases, Volume 172, Issue 6, December 1995, Pages 1425–1430, https://doi.org/10.1093/infdis/172.6.1425
- Share Icon Share
Abstract
An ELISA to detect serum IgG antibody response to human papillomavirus (HPV) type 16 viruslike particles (VLPs) was evaluated in a case-control study of cervical neoplasia, nested within a prospective cohort study. Subjects included 688 controls with continued normal cytology and 152 cases with confirmed incident squamous intraepithelial lesions who were tested for DNA of a broad spectrum of HPV types at cohort enrollment and follow-up. Of controls, 16.6% were seropositive compared with 30.8% and 52.4% of cases with low- and high-grade lesions, respectively. Of HPV16 DNA-negative subjects, 16.5% were seropositive. Seropositivity increased from 22.2% in subjects who were HPV-16 DNA- positive by polymerase chain reaction once only (enrollment or follow-up) to 83.3% in those who were HPV-16 DNA-positive at both time points. These data imply that serum antibody to HPV-16 VLPs is a relatively sensitive indicator of persisting cervical HPV-16 infection.